Emerging targets for the pharmacological treatment of depression: Focus on melatonergic system

Current Medicinal Chemistry

Volumn 19, Issue 3, 2012, Pages 428-437

  Catena Dell'Osso, Mario ^a   Marazziti, Donatella ^b   Rotella, Francesco ^c   Bellantuono, Cesario ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Agomelatine; Antidepressants; Arylalkylamine N acetyltransferase (AANAT); Depression; Melatonin; Melatonin receptors; Ramalteon

Indexed keywords

AGOMELATINE; ESCITALOPRAM; FLUOXETINE; MELATONIN; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR; MELATONIN DERIVATIVE; PAROXETINE; QR2; RAMELTEON; SERTRALINE; UNCLASSIFIED DRUG; VENLAFAXINE;

ABSENCE OF SIDE EFFECTS; ADJUVANT THERAPY; BINDING AFFINITY; BLOOD BRAIN BARRIER; BODY TEMPERATURE; CATABOLISM; CATALYSIS; CELL DIVISION; CELL FUNCTION; CELL GROWTH; CEREBROSPINAL FLUID; CIRCADIAN RHYTHM; CIRCADIAN RHYTHM SLEEP DISORDER; DARKNESS; DEGRADATION; DEPRESSION; DIET SUPPLEMENTATION; DNA SYNTHESIS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HEART RATE; HORMONE METABOLISM; HORMONE SYNTHESIS; HUMAN; INSOMNIA; KIDNEY FUNCTION; LIGHT; LIPOPHILICITY; LIVER FUNCTION; MAJOR DEPRESSION; MEMORY; MOTOR PERFORMANCE; MULTICENTER STUDY (TOPIC); NEUROPROTECTION; NONHUMAN; OSCILLATION; OSCILLATOR; OXIDATIVE STRESS; PHOSPHORYLATION; PHOTORECEPTOR; PINEAL BODY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SLEEP QUALITY; SUPERIOR CERVICAL GANGLION; SUPRACHIASMATIC NUCLEUS; WEIGHT GAIN;

EID: 84857762988     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803414277     Document Type: Review

References (168)

1. Andrade, L.; Caraveo-Anduaga, J.J.; Berglund, P. The epidemiology of major depressive episodes: Results from the International Consortium of Psychiatric Epidemiology (ICPE) Surveys. Int. J. Methods Psychiatr. Res., 2003, 12, 3-21. (Pubitemid 36675444)
2. Kessler, R.C.; Berglund, P.; Demler, O. The epidemiology of major depressive disorder: Results from the National Comorbidity Survey Replication (NCS-R). JAMA, 2003, 289, 3095-3105. (Pubitemid 37432885)
3. Weich, S.; Lewis, G. Poverty, unemployment, and common mental disorders: Population based cohort study. BMJ, 1998, 8, 317-315.
4. Maes, M.; Meltzer, H.Y. In: Psychopharmacology, The Fourth Generation of Progress, Bloom & Kupfer, eds.; Raven Press: New York, 1995, pp. 933- 944.
5. Owens, M.J.; Nemeroff, C.B. The serotonin transporter and depression. Depress. Anxiety, 1998, 8, 5-12. (Pubitemid 28524840)
6. Marazziti, D.; Dell'Osso, L.; Rossi, A.; Masala, I.; Baroni, S.; Armani, A.; Giannaccini, G.; Di Nasso, E.; Lucacchini, A.; Cassano, G.B. Decreased platelet [3H]paroxetine binding sites in suicide attempters. Psych. Res., 2001, 20, 103, 125-131. (Pubitemid 32817074)
7. Shildkraut, J.J. The catecholamine hypotesis of affective disorders : A review of supporting evidences. Am. J Psychiatry, 1965, 122, 509.
8. Lapin, I.P.; Oxenkrug, G.F. Intensification of the central serotonergic processes as a possible determinant of the thymoleptic effect. Lancet, 1969, 1, 132-136.
9. Stahl, M.S. Stahl's essential psychopharmacology. Neuroscientific basis and practical applications. 3rd ed.; Cambridge University Press: New York, 2008.
10. Marazziti, D.; Catena Dell'Osso, M.; Consoli, G.; Baroni, S. Second messenger modulation: A novel target of future antidepressants? Curr. Med. Chem., 2009, 16, 4679-4690.
11. Marazziti, D.; Catena Dell'osso M. The role of oxytocin in neuropsychiatric disorders. Curr. Med. Chem., 2008, 15, 698-704. (Pubitemid 351516805)
12. Sartorius, N.; Baghai, T.C.; Baldwin, D.S.; Barrett, B.; Brand, U.; Fleischhacker, W.; Goodwin, G.; Grunze, H.; Knapp, M.; Leonard, B.E.; Lieberman, J.; Nakane, Y.; Pinder, R.M.; Schatzberg, A.F.; Svestka, J.; Baumann, P.; Ghalib, K.; Markowitz, J.C.; Padberg, F.; Fink, M.; Furukawa, T.; Fountoulakis, K.N.; Jensen, P.; Kanba, S.; Riecher-Rössler, A. Antidepressant medications and other treatments of depressive disorders: A CINP Task Force report based on a review of evidence. Int. J. Neuropsychopharmacol., 2007, 10, s1-207.
13. Millan MJ. Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application. Pharmacol. Ther., 2006, 110, 135-370.
14. Catena-Dell'Osso, M.; Bellantuono, C.; Consoli, G.; Baroni, S.; Rotella, F.; Marazziti, D. Inflammatory and neurodegenerative pathways in depression: A new avenue for antidepressant development? Curr. Med. Chem., 2011, 18, 245-255.
15. Coric, V.; Taskiran, S.; Pittenger, C.; Wasylink, S.; Mathalon, D.H.; Valentine, G.; Saksa, J.; Wu, Y.T.; Gueorguieva, R.; Sanacora, G.; Malison, R.T.; Krystal, J.H. Riluzole augmentation in treatment-resistant obsessivecompulsive disorder: An open-label trial. Biol. Psychiatry, 2005, 1, 424-428. (Pubitemid 41219711)
16. Zarate, C.A.; Quiroz, J.A.; Singh, J.B.; Denicoff, K.D.; De Jesus, G.; Luckenbaugh, D.A.; Charney, D.S.; Manji, H.K. An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol. Psychiatry, 2005, 15, 430-432. (Pubitemid 40215774)
17. Sanacora, G.; Kendell, S.F.; Levin, Y.; Simen, A.A.; Fenton, L.R.; Coric, V.; Krystal, J.H. Preliminary evidence of riluzole efficacy in antidepressanttreated patients with residual depressive symptoms. Biol. Psychiatry, 2007, 15, 822-825. (Pubitemid 46330247)
18. Preskorn, S.H.; Baker, B.; Kolluri, S.; Menniti, F.S.; Krams, M.; Landen, J.W. An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP- 101,606, in patients with treatment-refractory major depressive disorder. J. Clin. Psychopharmacol., 2008, 28, 631-637.
19. Binneman, B.; Feltner, D.; Kolluri, S.; Shi, Y.; Qiu, R.; Stiger, T. A 6-week randomized, placebo-controlled trial of CP-316,311 (a selective CRH1 antagonist) in the treatment of major depression. Am. J. Psychiatry, 2008, 165, 617-620. (Pubitemid 351705339)
20. Kramer, M.S.; Winokur, A.; Kelsey, J.; Preskorn, S.H.; Rothschild, A.J.; Snavely, D.; Ghosh, K.; Ball, W.A.; Reines, S.A.; Munjack, D.; Apter, J.T.; Cunningham, L.; Kling, M.; Bari, M.; Getson, A.; Lee, Y. Demonstration of the efficacy and safety of a novel substance P (NK1)receptor antagonist in major depression. Neuropsychopharmacology, 2004, 29, 385-392. (Pubitemid 38180456)
21. Levine, J.; Barak, Y.; Gonzalves, M.; Szor, H.; Elizur, A.; Kofman, O.; Belmaker, R.H. Double-blind, controlled trial of inositol treatment of depression. Am. J. Psychiatry, 1995, 152, 792-794.
22. Benjamin, J.; Levine, J.; Fux, M.; Aviv, A.; Levy, D.; Belmaker, R.H. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am. J. Psychiatry, 1995, 152, 1084-1086.
23. Chengappa, K.N.; Levine, J.; Gershon, S.; Mallinger, A.G.; Hardan, A.; Vagnucci, A.; Pollock, B.; Luther, J.; Buttenfield, J.; Verfaille, S.; Kupfer, D.J. Inositol as an add-on treatment for bipolar depression. Bipolar Disord., 2000, 2, 47-55.
24. Eden Evins, A.; Demopulos, C.; Yovel, I.; Culhane, M.; Ogutha, J.; Grandin, L.D.; Nierenberg, A.A.; Sachs, G.S. Inositol augmentation of lithium or valproate for bipolar depression. Bipolar Disord., 2006, 8, 168-174. (Pubitemid 44026769)
25. Fleurence, R.; Williamson, R.; Jing, Y.; Kim, E.; Tran, Q.V.; Pikalov, A.S., Thase, M.E. A systematic review of augmentation strategies for patients with major depressive disorder. Psychopharmacol. Bull., 2009, 42, 57-90.
26. Manji, H.K.; Quiroz, J.A.; Sporn, J.; Payne, J.L.; Denicoff, K.A.; Gray, N.; Zarate, C.A.; Charney, D.S. Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol. Psychiatry, 2003, 15, 707-742. (Pubitemid 39658487)
27. Malkesman, O.; Austin, D.R.; Tragon, T.; Henter, I.D.; Reed, J.C.; Pellecchia, M.; Chen, G.; Manji, H.K. Targeting the BH3-interacting domain death agonist to develop mechanistically unique antidepressants. Mol. Psychiatry, 2011, Jul 5.
28. De Bodinat, C.; Guardiola-Lemaitre, B.; Mocaër, E.; Renard, P.; Muñoz, C.; Millan, M.J. Agomelatine, the first melatonergic antidepressant: Discovery, characterization and development. Nat. Rev. Drug Discov., 2010, 9, 628-642.
29. Lerner, A.B.; Case, J.D.; Takahashi, Y.; Lee, T.H., Mori, W. Isolation of melatonin, the pineal factor that lightens melanocytes. J. Am. Chem. Soc., 1958, 89, 2857-2858.
30. Hardeland, R.; Poeggeler, B. Non-vertebrate melatonin. J. Pineal Res., 2003, 34, 233-241. (Pubitemid 36469768)
31. Hattori, A.; Migitaka, H.; Iigo, M.; Itoh, M.; Yamamoto, K.; Ohtani-Kaneko, R.; Hara, M.; Suzuki, T.; Reiter, R.J. Identification of melatonin in plants and its effects on plasma melatonin levels and binding to melatonin receptors in vertebrates. Biochem. Mol. Biol. Int., 1995, 35, 627-634. (Pubitemid 26177836)
32. Reiter, R.J. Pineal melatonin: Cell biology of its synthesis and of its physiological interactions. Endocr. Rev., 1991, 12, 151-180.
33. Zawilska, J.B.; Skene, D.J.; Arendt, J. Physiology and pharmacology of melatonin in relation to biological rhythms. Pharmacol. Rep., 2009, 61, 383-410.
34. Hardeland, R. Melatonin metabolism in the central nervous system. Curr. Neuropharmacol., 2010, 8:168-181.
35. Berson, D.M.; Dunn, F.A.; Takao, M. Phototransduction by retinal ganglion cells that set the circadian clock. Science, 2002, 8, 1070-1073. (Pubitemid 34132236)
36. Klein, D.C. In: Light and Biological Rhythms in Man, Wetterberg, ed.; Pergamon Press: London, 1993, pp. 55-71.
37. Karolczak, M.; Korf, H.W.; Stehle, J.H. The rhythm and blues of gene expression in the rodent pineal gland. Endocrine, 2005, 27, 89-100. (Pubitemid 41558441)
38. Zawilska, J.B.; Wawrocka, M. Chick retina and pineal gland differentially respond to constant light and darkness: In vivo studies on serotonin Nacetyltransferase (NAT) activity and melatonin content. Neurosci. Lett., 1993, 153, 21-24. (Pubitemid 23147027)
39. Arendt, J. Melatonin and the Mammalian Pineal Gland. Chapman & Hall: London, 1995.
40. Lucas, R.J.; Freedman, M.S.; Muñoz, M.; Garcia-Fernández, J.M.; Foster, R.G. Regulation of the mammalian pineal by non-rod, non-cone, ocular photoreceptors. Science, 1999, 284, 505-507. (Pubitemid 29289627)
41. Brainard, G.C.; Hanifin, J.P.; Greeson, J.M.; Byrne, B.; Glickman, G.; Gerner, E.; Rollag, M.D. Action spectrum for melatonin regulation in humans: Evidence for a novel circadian photoreceptor. J. Neurosci., 2001, 21, 6405-6412. (Pubitemid 32737772)
42. Hankins, M.W.; Peirson, S.N.; Foster, R.G. Melanopsin: An exciting photopigment. Trends Neurosci., 2008, 31, 27-36.
43. Klein, D.C. Arylalkylamine N-acetyltransferase: "the Timezyme". J. Biol. Chem., 2007, 282, 4233-4237.
44. Florez, J.C.; Seidenman, K.J.; Barrett, R.K.; Sangoram, A.M.; Takahashi, J.S. Molecular cloning of chick pineal tryptophan hydroxylase and circadian oscillation of its mRNA levels. Mol. Brain Res., 1996, 42, 25-30. (Pubitemid 26345402)
45. Sudgen, D. Comparison of circadian expression of tryptophan hydroxylase isoform mRNAs in the rat pineal gland using real-time PCR. J. Neurochem., 2003, 86, 1308-1311.
46. Zimmermann, R.C.; McDougle, C.J.; Schumacher, M.; Olcese, J.; Mason, J.W.; Heninger, G.R.; Price, L.H. Effects of acute tryptophan depletion on nocturnal melatonin secretion in humans. J. Clin. Endocrinol. Metab., 1993, 76, 1160-1164. (Pubitemid 23155429)
47. Iuvone, P.M.; Tosini, G.; Pozdeyev, N.; Haque, R.; Klein, D.C.; Chaurasia, S.S. Circadian clocks, clock networks, arylalkylamine N-acetyltransferase, and melatonin in the retina. Prog. Retin Eye Res., 2005, 24, 433-456. (Pubitemid 40552811)
48. Zawilska, J.B.; Lorenc, A.; Bereziñska, M.; Vivien-Roels, B.; Pévet, P.; Skene, D.J. Photoperiod-dependent changes in melatonin biosynthesis in the turkey pineal gland and retina. Poultry Sci., 2007, 86, 1397-1405. (Pubitemid 47580959)
49. Dubocovich, M.L.; Delagrange, P.; Krause, D.N.; Sugden, D.; Cardinali, D.P.; Olcese, J. International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G proteincoupled melatonin receptors. Pharmacol. Rev., 2010, 62, 343-380.
50. Schomerus, C.; Korf, H.W. Mechanisms regulating melatonin synthesis in the mammalian pineal organ. Ann. NY Acad. Sci., 2005, 1057, 372-383. (Pubitemid 43211647)
51. Pozdeyev, N.; Taylor, C.; Haque, R.; Chaurasia, S.S.; Visser, A.; Thazyeen, A.; Du, Y.; Fu, H.; Weller, J.; Klein, D.C.; Iuvone, P.M. Photic regulation of arylalkylamine N-acetyltransferase binding to 14-3-3 proteins in retinal photoreceptor cells. J. Neurosci., 2006, 26, 9153-9161. (Pubitemid 44359842)
52. Rosiak, J.; Iuvone, P.M.; Zawilska, J.B. UV-A light regulation of arylalkylamine N-acetyltransferase activity in the chick pineal gland: Role of cAMP and proteasomal proteolysis. J. Pineal Res., 2005, 39, 419-425.
53. Leston, J.; Harthé, C.; Brun, J.; Mottolese, C.; Mertens, P.; Sindou, M.; Claustrat, B. Melatonin is release in the third ventricle in humans. A study in movement disorders. Neurosci. Lett., 2009, 469, 294-297.
54. Pang, S.F.; Brown, G.M. Regional concentrations of melatonin in the rat brain in the light and dark period. Life Sci., 1983, 33, 1199-1204. (Pubitemid 13006215)
55. Lahiri, D.K.; Ge, Y.-W.; Sharman. E.H.; Bondy, S.C. Age related changes in serum melatonin in mice: Higher levels of combined melatonin and 6- hydroxymelatonin sulfate in the cerebral cortex than serum, heart, liver and kidney tissues. J. Pineal Res., 2004, 36, 217-223. (Pubitemid 38530468)
56. Cardinali, D.P.; Lynch, H.J.; Wurtman, R.J. Binding of melatonin to human and rat plasma proteins. Endocrinology, 1972, 91, 1213-1218.
57. Morin, D.; Simon, N.; Deprés-Brummer, P.; Lévi, F.; Tillement, J.P.; Urien, S. Melatonin high-affinity binding to alpha-1-acid glycoprotein in human serum. Pharmacology, 1997, 54, 271-275. (Pubitemid 27326258)
58. Kennaway, D.J.; Voultsios, A. Circadian rhythm of free melatonin in human plasma. J. Clin. Endocrinol. Metab., 1998, 83, 1013-1015 (Pubitemid 28496485)
59. Ma, X.; Chen, C.; Krausz, K.W.; Idle, J.R.; Gonzalez, F.J. A metabolomic perspective of melatonin metabolism in the mouse. Endocrinology, 2008, 149, 1869-1879. (Pubitemid 351468324)
60. Hardeland, R. Antioxidative protection by melatonin - Multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine, 2005, 27, 119-130. (Pubitemid 41558444)
61. Hardeland, R.; Backhaus, C.; Fadavi, A.; Hess, M. N1- acetyl-5- methoxykynuramine contrasts with other tryptophan metabolites by a peculiar type of NO scavenging: Cyclization to a cinnolinone prevents formation of unstable nitrosamines. J. Pineal Res., 2007, 43, 104-105. (Pubitemid 47035215)
62. Hardeland, R.; Tan, D.-X.; Reiter, R.J. Kynuramines, metabolites of melatonin and other indoles: The resurrection of an almost forgotten class of biogenic amines. J. Pineal Res., 2009, 47, 109-126.
63. Hirata, F.; Hayaishi, O.; Tokuyama, T.; Senoh, S. In vitro and in vivo formation of two new metabolites of melatonin. J. Biol. Chem., 1974, 249, 1311-1313.
64. Cardinali, D.P.; Vacas, M.I.; Boyer, E.E. Specific binding of melatonin in bovine brain. Endocrinology, 1979, 105, 437-441. (Pubitemid 9241022)
65. Dubocovich, M.L. Melatonin is a potent modulator of dopamine release in the retina. Nature, 1983, 306, 782-784. (Pubitemid 14206041)
66. Dubocovich, M.L. Characterization of a retinal melatonin receptor. J. Pharmacol. Exp. Ther., 1985, 234, 395-401. (Pubitemid 15241859)
67. Dubocovich, M.L. Luzindole (N-0774): A novel melatonin receptor antagonist. J. Pharmacol. Exp. Ther., 1988, 246, 902-910.
68. Dubocovich, M.L. Pharmacology and function of melatonin receptors. FASEB J., 1988, 2, 2765-2773.
69. Vakkuri, O.; Lämsä, E.; Rahkamaa, E.; Ruotsalainen, H.; Leppäluoto, J. Iodinated melatonin: Preparation and characterization of the molecular structure by mass and 1H NMR spectroscopy. Anal Biochem.,1984, 142, 284-289. (Pubitemid 15177261)
70. Dubocovich, M.L., Takahashi, J.S. Use of 2-[125I]iodomelatonin to characterize melatonin binding sites in chicken retina. Proc Natl Acad Sci USA, 1987, 84, 3916-3920. (Pubitemid 17088390)
71. Reppert, S.M.; Weaver, D.R.; Ebisawa, T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron, 1994, 13, 1177-1185. (Pubitemid 24372135)
72. Reppert, S.M.; Weaver, D.R. Melatonin madness. Cell, 1995, 83, 1059-1062. (Pubitemid 26007796)
73. Reppert, S.M.; Weaver, D.R.; Cassone, V.M.; Godson, C.; Kolakowski, L.F. Melatonin receptors are for the birds: Molecular analysis of two receptor subtypes differentially expressed in chick brain. Neuron, 1995, 15, 1003-1015.
74. Reppert, S.M.; Weaver, D.R.; Godson, C. Melatonin receptors step into the light: Cloning and classification of subtypes. Trends Pharmacol Sci, 1996, 17, 100-102. (Pubitemid 26111451)
75. Nosjean, O.; Ferro, M.; Coge, F.; Beauverger, P.; Henlin, J.M.; Lefoulon, F.; Fauchere, J.L.; Delagrange, P.; Canet, E.; Boutin, J.A. Identification of the melatoninbinding site MT3 as the quinone reductase 2. J. Biol. Chem., 2000, 275, 31311-31317.
76. Dubocovich, M.L.; Riviera-Bermudez, M.A.; Gerdin, M.J.; Masana, M.I. Molecular pharmacology, regulation and function of mammalian melatonin receptors. Front. Biosci., 2003, 8, 1093-1098.
77. McNulty, S.; Ross, A.W.; Shiu, K.Y.; Morgan, P.J.; Hastings, M.H. Phosphorylation of CREB in ovine pars tuberalis is regulated both by cyclic AMP-dependent and cyclic AMP-independent mechanisms. J. Neuroendocrinol., 1996, 8, 635-645. (Pubitemid 26270917)
78. Capsoni, S.; Viswanathan, M.; De Oliveira, A.M.; Saavedra, J.M. Characterization of melatonin receptors and signal transduction system in rat arteries forming the circle of Willis. Endocrinology, 1994, 135, 373-378. (Pubitemid 24203840)
79. Morgan, P.J.; Barrett, P.; Howell, H.E.; Helliwell, R. Melatonin receptors: Localization, molecular pharmacology and physiological significance. Neurochem. Int., 1994, 24, 101-146. (Pubitemid 24061864)
80. Radio, N.M.; Doctor, J.S.; Witt-Enderby, P.A. Melatonin enhances alkaline phosphatase activity in differentiating human adult mesenchymal stem cells grown in osteogenic medium via MT2 melatonin receptors and the MEK/ERK (1/2) signaling cascade. J. Pineal Res., 2006, 40, 332-342.
81. Nelson, C.S.; Marino, J.L.; Allen, C.N. Melatonin receptors activate heteromeric G-protein coupled Kir3 channels. Neuroreport, 1996, 7, 717-720. (Pubitemid 26145328)
82. Nelson, C.S.; Ikeda, M.; Gompf, H.S.; Robinson, M.L.; Fuchs, N.K.; Yoshioka, T.; Neve, K.A.; Allen, C.N. Regulation of melatonin 1a receptor signaling and trafficking by asparagine-124. Mol. Endocrinol., 2001, 15, 1306-1317. (Pubitemid 32703479)
83. Jiang, Z.G.; Nelson, C.S.; Allen, C.N. Melatonin activates an outward current and inhibits Ih in rat suprachiasmatic nucleus neurons. Brain Res., 1995, 687, 125-132.
84. Mason, R.; Brooks, A. The electrophysiological effects of melatonin and a putative melatonin antagonist (N-acetyltryptamine) on rat suprachiasmatic neurones in vitro. Neurosci. Lett., 1988, 95, 296-301.
85. Shibata, S.; Cassone, V.M.; Moore, R.Y. Effects of melatonin on neuronal activity in the rat suprachiasmatic nucleus in vitro. Neurosci. Lett., 1989, 97, 140-144. (Pubitemid 19048925)
86. Stehle, J.; Vanecek, J.; Vollrath, L. Effects of melatonin on spontaneous electrical activity of neurons in rat suprachiasmatic nuclei: An in vitro iontophoretic study. J. Neural. Transm., 1989, 78, 173-177. (Pubitemid 19246663)
87. McArthur, A.J.; Hunt, A.E.; Gillette, M.U. Melatonin action and signal transduction in the rat suprachiasmatic circadian clock: Activation of protein kinase C at dusk and dawn. Endocrinology, 1997, 138, 627-634. (Pubitemid 27110912)
88. Godson, C.; Reppert, S.M. The Mel1a melatonin receptor is coupled to parallel signal transduction pathways. Endocrinology, 1997, 138, 397-404. (Pubitemid 27009449)
89. Sharkey, J.; Olcese, J. Transcriptional inhibition of oxytocin receptor expression in human myometrial cells by melatonin involves protein kinase C signaling. J. Clin. Endocrinol. Metab., 2007, 92, 4015-4019. (Pubitemid 47607654)
90. Sharkey, J.T.; Puttaramu, R.; Word, R.A.; Olcese, J. Melatonin synergizes with oxytocin to enhance contractility of human myometrial smooth muscle cells. J. Clin. Endocrinol. Metab., 2009, 94, 421-427
91. Gilad, E.; Pick, E.; Matzkin, H.; Zisapel, N. Melatonin receptors in benign prostate epithelial cells: Evidence for the involvement of cholera and pertusis toxin-sensitive G proteins in their signal transduction pathways. Prostate, 1998, 35, 27-34. (Pubitemid 28158634)
92. Petit, L.; Lacroix, I.; de Coppet, P.; Strosberg, A.D.; Jockers, R. Differential signaling of human Mel1a and Mel1b melatonin receptors through the cyclic guanosine 3-5-monophosphate pathway. Biochem. Pharmacol., 1999, 58, 633-639. (Pubitemid 29296883)
93. Mazurais, D.; Brierley, I.; Anglade, I.; Drew, J.; Randall, C.; Bromage, N.; Michel, D.; Kah, O.; Williams, L.M. Central melatonin receptors in the rainbow trout: Comparative distribution of ligand binding and gene expression. J. Comp. Neurol., 1999, 409, 313-324. (Pubitemid 29264262)
94. Natesan, A.K.; Cassone, V.M. Melatonin receptor mRNA localization and rhythmicity in the retina of the domestic chick, Gallus domesticus. Vis Neurosci., 2002, 19, 265-274. (Pubitemid 36221907)
95. Wu, Y.H.; Zhou, J.N.; Balesar, R.; Unmehopa, U.; Bao, A.; Jockers, R.; Van Heerikhuize, J.; Swaab, D.F. Distribution of MT1 melatonin receptor immunoreactivity in the human hypothalamus and pituitary gland: Colocalization of MT1 with vasopressin, oxytocin, and corticotropinreleasing hormone. J. Comp. Neurol., 2006, 499, 897-910 (Pubitemid 44892817)
96. Alarma-Estrany, P.; Pintor, J. Melatonin receptors in the eye: Location, second messengers and role in ocular physiology. Pharmacol. Ther., 2007, 113, 507-522. (Pubitemid 46365956)
97. Pozo, D.; Delgado, M.; Fernandez-Santos, J.M.; Calvo, J.R.; Gomariz, R.P.; Martin-Lacave, I.; Ortiz, G.G.; Guerrero, J.M. Expression of the Mel1amelatonin receptor mRNA in T and B subsets of lymphocytes from rat thymus and spleen. FASEB J, 1997, 11, 466-473. (Pubitemid 27259988)
98. Masana, M.I.; Doolen, S.; Ersahin, C.; Al-Ghoul, W.M.; Duckles, S.P.; Dubocovich, M.L.; Krause, D.N. MT2 melatonin receptors are present and functional in rat caudal artery. J. Pharmacol. Exp. Ther., 2002, 302, 1295-1302. (Pubitemid 34920255)
99. Naji, L.; Carrillo-Vico, A.; Guerrero, J.M.; Calvo, J.R. Expression of membrane and nuclear melatonin receptors in mouse peripheral organs. Life Sci., 2004, 74, 2227-2236. (Pubitemid 38249544)
100. Slominski, A.; Tobin, D.J.; Zmijewski, M.A.; Wortsman, J.; Paus, R. Melatonin in the skin: Synthesis, metabolism and functions. Trends Endocrinol. Metab., 2007, 19, 17-24.
101. Richter, H.G.; Torres-Farfan, C.; Garcia-Sesnich, J.; Abarzua-Catalan, L.; Henriquez, M.G.; Alvarez-Felmer, M.; Gaete, F.; Rehren, G.E.; Seron-Ferre, M. Rhythmic expression of functional MT1 melatonin receptors in the rat adrenal gland. Endocrinology, 2008, 149, 995-1003. (Pubitemid 351397921)
102. Mazzoccoli, G.; Southern, R.B.; De Cata, A.; Giuliani, F.; Fontana, A.; Copetti, M.; Pellegrini, F.; Tarquini, R. A timetable of 24-hour patterns for human lymphocyte subpopulations. J. Biol. Regul. Homeost. Agents, 2011, 25, 387-395.
103. Richter, H.G.; Torres-Farfán, C.; Rojas-García, P.P.; Campino, C.; Torrealba, F.; Serón-Ferré, M. The circadian timing system: Making sense of day/night gene expression. Biol. Res., 2004, 37, 11-28. (Pubitemid 38786639)
104. Hardeland, R.; Madrid, J.A.; Tan, D.X.; Reiter, R.J. Melatonin, the circadian multioscillator system and health: The need for detailed analyses of peripheral melatonin signaling. J. Pineal Res., 2011, Sep 27.
105. Kalsbeek, A.; Buijs, R.M. Output pathways of the mammalian suprachiasmatic nucleus: Coding circadian time by transmitter selection and specific targeting. Cell Tissue Res., 2002, 309, 109-118. (Pubitemid 34744033)
106. Sakamoto, K.; Nagase, T.; Fukui, H.; Horikawa, K.; Okada, T.; Tanaka, H.; Sato, K.; Miyake, Y.; Ohara, O.; Kako, K. Multitissue circadian expression of rat period homolog (rPer2) mRNA is governed by the mammalian circadian clock, the suprachiasmatic nucleus in the brain. J. Biol. Chem., 1998, 273, 27039-27042. (Pubitemid 28500404)
107. Balsalobre, A. Clock genes in mammalian peripheral tissues. Cell Tissue Res., 2002, 309, 193-199. (Pubitemid 34744041)
108. Von Gall, C.; Garabette, M.L.; Kell, C.A.; Frenzel, S.; Dehghani, F.; Schumm-Draeger, P.M.; Weaver, D.R.; Korf, H.W.; Hastings, M.H.; Stehele, J.H. Rhythmic gene expression in pituitary depends on heterologous sensitization by the neurohormone melatonin. Nat. Neurosci., 2002, 5, 234-238. (Pubitemid 34171136)
109. Wyatt, J.K. Circadian rhythm sleep disorders. Pediatr. Clin. North Am., 2011, 58, 621-635.
110. Lerner, A.B.; Nordlund, J.J. Melatonin: Clinical pharmacology. J. Neural Transm., 1978, 13, s339-347.
111. Lavie, P. Melatonin: Role in gating nocturnal rise in sleep propensity. J. Biol. Rhythms, 1997, 12, 657-665. (Pubitemid 127477103)
112. Lockley, S.W.; Skene, D.J.; Tabandeh, H.; Bird, A.C.; Defrance, R.; Arendt, J. Relationship between napping and melatonin in the blind. J. Biol. Rhythms, 1997, 12, 16-25. (Pubitemid 127493103)
113. Kräuchi, K.; Cajochen, C.; Pache, M.; Flammer, J.; Wirz-Justice, A. Thermoregulatory effects of melatonin in relation to sleepiness. Chronobiol. Int., 2006, 23, 475-484. (Pubitemid 43739058)
114. Adachi, A.; Nogi, T.; Ehibara, S. Phase-relationship and mutual effects between circadian rhythms of ocular melatonin and dopamine in the pigeon. Brain Res., 1998, 792, 361-369. (Pubitemid 28267556)
115. Skene, D.J.; Lockley, S.W.; Arendt, J. Use of melatonin in the treatment of phase shift and sleep disorders. Adv. Exp. Med. Biol., 1999, 467, 79-84.
116. Brzezinski, A.; Vangel, M.G.; Wurtman, R.J.; Norrie, G.; Zhdanova, I.; Ben- Shushan, A.; Ford, I. Effects of exogenous melatonin on sleep: A metaanalysis. Sleep Med. Rev., 2005, 9, 41-50. (Pubitemid 40092917)
117. Scheer, F.A.; Czeisler, C.A. Melatonin, sleep, and circadian rhythms. Sleep Med. Rev., 2005, 9, 5-9.
118. Deacon, S.; Arendt, J. Melatonin-induced temperature suppression and its acute phase-shifting effects correlate in a dose-dependent manner in humans. Brain Res., 1995, 688, 77-85.
119. Kräuchi, K.; Cajochen, C.; Möri, D.; Graw, P.; Wirz-Justice, A. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am. J. Physiol., 1997, 272, R1178-R1188.
120. Rajaratnam, S.M.; Dijk, D.J.; Middleton, B.; Stone, B.M.; Arendt, J. Melatonin phase-shifts human circadian rhythms with no evidence of changes in the duration of endogenous melatonin secretion or the 24-hour production of reproductive hormones. J. Clin. Endocrinol. Metab., 2003, 88, 4303-4309. (Pubitemid 37153735)
121. Burgess, H.J.; Revell, V.L.; Eastman, C.I. A three pulse phase response curve to three milligrams of melatonin in humans. J. Physiol., 2008, 586, 639-647.
122. Middleton, B.; Arendt, J.; Stone, B.M. Complex effects of melatonin on human circadian rhythms in constant dim light. J. Biol. Rhythms, 1997, 12, 467-477. (Pubitemid 127478561)
123. Hazlerigg, D.G., Wagner, G.C. Seasonal photoperiodism in vertebrates: From coincidence to amplitude. Trends Endocrinol. Metab., 2006, 17, 83-91.
124. Hastings, M.H.; Herbert, J.; Martensz, N.D.; Roberts, A.C. Annual reproductive rhythms in mammals: Mechanisms of light synchronization. Ann. NYAcad. Sci., 1985, 453, 182-204. (Pubitemid 16169259)
125. Arendt, J. Role of the pineal gland and melatonin in seasonal reproductive function in mammals. Oxf. Rev. Repr. Biol., 1986, 8, 266-320.
126. Chemineau, P.; Malpaux, B. Melatonin and reproduction in domestic farm animals (French). Therapie, 1998, 53, 445-452. (Pubitemid 29002813)
127. Etain, B.; Milhiet, V.; Bellivier, F.; Leboyer, M. Genetics of circadian rhythms and mood spectrum disorders. Eur. Neuropsychopharmacol., 2011, Aug 9.
128. Germain, A.; Kupfer, D.J. Circadian rhythm disturbances in depression. Hum. Psychopharmacol., 2008, 23, 571-?585.
129. Souetre, E.; Salvati, E.; Belugou, J.L.; Pringuey, D.; Candito, M.; Krebs, B.; Ardisson, J.L.; Darcourt, G. Circadian rhythms in depression and recovery: Evidence for blunted amplitude as the main chronobiological abnormality. Psychiatry Res., 1989, 28, 263-278. (Pubitemid 19165767)
130. Miller, J.D.; Morin, L.P.; Schwartz, W.J.; Moore, R.Y. New insights into the mammalian circadian clock. Sleep, 1996, 19, 641-667.
131. Czeisler, C.A.; Buxton, O.M.; Khalsa, S.B.S. In: Principles and practice of sleep medicine, 4th ed, Kryger, Roth, Dement, eds; WB Saunders: Philadelphia, 2005, pp. 375-394.
132. Faravelli, C.; Amedei, S.G.; Rotella, F.; Faravelli, L.; Palla, A.; Consoli, G.; Ricca, V.; Batini, S.; Lo Sauro, C.; Spiti, A.; Catena Dell'Osso, M. Childhood traumata, Dexamethasone Suppression Test and psychiatric symptoms: A trans-diagnostic approach. Psychol. Med., 2010, 40, 2037-2048.
133. Hickie, I.; Davenport, T.; Wakefield, D.; Vollmer-Conna, U.; Cameron, B.; Vernon, S.D.; Reeves, W.C.; Lloyd, A.; Dubbo Infection Outcomes Study Group. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: Prospective cohort study. BMJ, 2006, 333, 575.
134. Rogers, N.L.; Dinges, D.F.; Kennaway, D.J.; Dawson, D. Potential action of melatonin in insomnia. Sleep, 2003, 26, 1058-1059. (Pubitemid 39619771)
135. Kopp, C.; Vogel, E.; Rettori, M.C.; Delagrange, P.; Misslin, R. The effects of melatonin on the behavioural disturbances induced by chronic mild stress in C3H/He mice. Behav. Pharmacol., 1999, 10, 73-83. (Pubitemid 29106290)
136. Dalton, E.J.; Rotondi, D.; Levitan, R.D.; Kennedy, S.H.; Brown, G.M. Use of slow-release melatonin in treatment-resistant depression. J. Psychiatry Neurosci., 2000, 25, 48-52. (Pubitemid 30143328)
137. Hirsch-Rodriguez, E.; Imbesi, M.; Manev, R.; Uz, T.; Manev, H. The pattern of melatonin receptor expression in the brain may influence antidepressant treatment. Med. Hypoth., 2007, 69, 120-124. (Pubitemid 46686944)
138. Wright, K.P., Rogers, N.L. In: Melatonin: From molecules to therapy. Pandi- Perumal & Cardinali, eds.; Nova Science Publishers: New York, 2007, pp. 547-569.
139. Lemoine, P.; Nir, T.; Laudon, M.; Zisapel, N. Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J. Sleep Res., 2007, 16, 372-380. (Pubitemid 350151283)
140. Zlotos, D.P. Recent advances in melatonin receptor ligands. Arch. Pharm., 2005, 338, 229-247. (Pubitemid 40957262)
141. Rajaratnam, S.M.; Polymeropoulos, M.H.; Fisher, D.M.; Roth, T.; Scott, C.; Birznieks, G.; Klerman, E.B. Melatonin agonist tasimelteon (VEC-162) for transient insomnia after sleep-time shift: Two randomised controlled multicentre trials. Lancet, 2009, 373, 482-491.
142. Millan, M.J.; Gobert, A.; Lejeune, F.; Dekeyne, A.; Newman-Tancredi, A.; Pasteau, V.; Rivet, J.M.; Cussac, D. The novel melatonin agonist agomelatine (S20098) is an antagonist at 5-hydroxytryptamine2C receptors, blockade of which enhances the activity of frontocortical dopaminergic and adrenergic pathways. J. Pharmacol. Exp. Ther., 2003, 306, 954-964. (Pubitemid 37025301)
143. Racagni, G.; Riva, M.A.; Popoli, M. The interaction between the internal clock and antidepressant efficacy. Int. Clin. Psychopharmacol., 2007, 22, s9- 14. (Pubitemid 47530848)
144. Audinot, V.; Mailliet, F.; Lahaye-Brasseur, C.; Bonnaud, A.; Le Gall, A.; Amossé, C.; Dromaint, S.; Rodriguez, M.; Nagel, N.; Galizzi, J.P.; Malpaux, B.; Guillaumet, G.; Lesieur, D.; Lefoulon, F.; Renard, P.; Delagrange, P.; Boutin, J.A. New selective ligands of human cloned melatonin MT1 and MT2 receptors. Naunyn Schmiedebergs Arch. Pharmacol., 2003, 367, 553-561. (Pubitemid 36829452)
145. Lôo, H.; Hale, A.; D'haenen, H. Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: A placebo-controlled dose range study. Int. Clin. Psychopharmacol., 2002, 17, 239-247.
146. Kennedy, S.H.; Emsley, R. Placebo-controlled trial of agomelatine in the treatment of major depressive disorder. Eur. Neuropsychopharmacol., 2006, 16, 93-100. (Pubitemid 43145814)
147. Olié, J.P.; Kasper, S. Efficacy of agomelatine, a MT1/MT2 receptor agonist with 5-HT2C antagonistic properties, in major depressive disorder. Int. J. Neuropsychopharmacol., 2007, 10, 661-673. (Pubitemid 47517525)
148. Lemoine, P.; Guilleminault, C.; Alvarez, E. Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: Randomized, double-blind comparison with venlafaxine. J. Clin. Psychiatry, 2007, 68, 1723-1732. (Pubitemid 350247502)
149. Kasper, S.; Hajak, G.; Wulff, K.; Hoogendijk, W.J.; Montejo, A.L.; Smeraldi, E., Rybakowski, J.K.; Quera-Salva, M.A.; Wirz-Justice, A.M.; Picarel-Blanchot, F.; Baylé, F.J. Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: A randomized, doubleblind comparison with sertraline. J. Clin. Psychiatry, 2010, 71, 109-120.
150. Stahl, S.M.; Fava, M.; Trivedi, M.H.; Caputo, A.; Shah, A.; Post, A. Agomelatine in the treatment of major depressive disorder: An 8-week, multicenter, randomized, placebo-controlled trial. J. Clin. Psychiatry, 2010, 71, 616-626.
151. Zajecka, J.; Schatzberg, A.; Stahl, S.; Shah, A.; Caputo, A.; Post, A. Efficacy and safety of agomelatine in the treatment of major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled trial. J. Clin. Psychopharmacol., 2010, 30, 135-144.
152. Quera-Salva, M.A.; Hajak, G.; Keufer-Le Gall, S.; Nutt, D. Efficacy and safety of agomelatine in patients with major depressive disorder compared to escitalopram: A randomized, double-blind study. Int. J. Neuropsych., 2010, 13, 3-43.
153. Di Giannantonio, M.; Di Iorio, G.; Guglielmo, R.; De Berardis, D.; Conti, C.M.; Acciavatti, T.; Cornelio, M.; Martinotti, G. Major depressive disorder, anhedonia and agomelatine: An open-label study. J. Biol. Regul. Homeost. Agents, 2011, 25, 109-114.
154. Montgomery, S.A.; Kennedy, S.H.; Burrows, G.D.; Lejoyeux, M.; Hindmarch, I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: A randomized, double-blind, placebocontrolled discontinuation study. Int. Clin. Psychopharmacol., 2004, 19, 271-280. (Pubitemid 39141943)
155. Kennedy, S.H.; Rizvi, S.; Fulton, K.; Rasmussen, J. A double-blind comparison of sexual functioning, antidepressant efficacy, and tolerability between agomelatine and venlafaxine XR. J. Clin. Psychopharmacol., 2008, 28, 329-333.
156. Montejo, A.L.; Prieto, N.; Terleira, A.; Matias, J.; Alonso, S.; Paniagua, G.; Naval, S.; Parra, D.G.; Gabriel, C.; Mocaër, E.; Portolés, A. Better sexual acceptability of agomelatine (25 and 50 mg) compared with paroxetine (20 mg) in healthy male volunteers. An 8-week, placebo-controlled study using the PRSEXDQ-SALSEX scale. J. Psychopharmacol., 2010, 24, 111-120.
157. Goodwin, G.M.; Emsley, R.; Rembry, S.; Rouillon, F.; for the Agomelatine Study Group. Agomelatine prevents relapse in patients with major depressive disorder without evidence of a discontinuation syndrome: A 24-week randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry, 2009, 70, 1128-1137.
158. Hale, A.; Corral, R.M.; Mencacci, C.; Ruiz, J.S.; Severo, C.A.; Gentil, V. Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: A randomized, double-blind study. Int. Clin. Psychopharmacol., 2010, 25, 305-314.
159. Miyamoto, M. Pharmacology of ramelteon, a selective MT1/MT2 receptor agonist: A novel therapeutic drug for sleep disorders. CNS Neurosci. Ther., 2009, 15, 32-51.
160. Yukuhiro, N.; Kimura, H.; Nishikawa, H.; Ohkawa, S.; Yoshikubo, S.; Miyamoto, M. Effects of ramelteon (TAK-375) on nocturnal sleep in freely moving monkeys. Brain Res., 2004, 1027, 59-66. (Pubitemid 39370995)
161. Miyamoto, M.; Nishikawa, H.; Doken, Y.; Hirai, K.; Uchikawa, O.; Ohkawa, S. The sleep-promoting action of ramelteon (TAK-375) in freely moving cats. Sleep, 2004, 27, 1319-1325. (Pubitemid 44138898)
162. Fisher, S.P.; Davidson, K.; Kulla, A.; Sugden, D. Acute sleep-promoting action of the melatonin agonist, ramelteon, in the rat. J. Pineal Res., 2008, 45, 125-132.
163. Erman, M.; Seiden, D.; Zammit, G.; Sainati, S.; Zhang, J. An efficacy, safety, and dose-response study of Ramelteon in patients with chronic primary insomnia. Sleep Med., 2006, 7, 17-24. (Pubitemid 43033540)
164. Meier, P.J.; Ziegler, W.H.; Neftel, K. [Benzodiazepine-practice and problems of its use.] Schweizerische medizinische Wochenschrift, 1988, 118, 381-392.
165. Malliet, F.; Ferry, G.; Vella, F.; Thiam, K.; Delagrange, P.; Boutin, J.A. Organs from mice deleted for NRH quinone oxido reductase 2 are deprived of the melatonin binding site MT3. FEBS Lett., 2004, 578, 116-120. (Pubitemid 39576111)
166. Harada, S.; Fujii, C.; Hayashi, A.; Ohkoshi, N. An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: Glutathione-S-transferase M1 and quinine oxidoreductases 1 and 2. Biochem. Biophys Res. Commun., 2001, 288, 887-892. (Pubitemid 33140966)
167. Harada, S.; Tachikawa, H.; Kawanshi, Y. A possible association between an insertion/deletion polymorphism of the NQO2 gene and schizophrenia. Psychiat. Genetics, 2003, 13, 205-209. (Pubitemid 38033105)
168. Oxenkrug, G.F.; Bachurin, S.O.; Prakhie, W.; Zefirov, N.S. Quinone reductase 2 and antidepressant effect of melatonin derivatives. Ann. NY Acad. Sci., 2010, 1199, 121-124.